Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma

Mansour S. Al-Moundhri, A. Al-Shukaili, M. Al-Nabhani, B. Al-Bahrani, I. A. Burney, A. Rizivi, S. S. Ganguly

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Aim: To analyze the serum levels and prognostic significance of vascular endothelial growth factor (VEGF) -A, -C, and -D, and their receptors, VEGFR-1 and -2 in gastric adenocarcinomas. Methods: The serum levels of VEGF family members were measured in 76 control subjects and 76 patients with gastric adenocarcinoma using an enzyme-linked immunosorbent assay (ELISA). These measurements were correlated with clinco-pathological features and survival rates. Results: The serum levels of VEGF-A and its receptor, VEGFR-1, were significantly higher in patients with gastric cancer than in healthy donors (t = 2.3, P = 0.02 and t = 4.2, P <0.0001, respectively). In contrast, the serum levels of VEGF-D were significantly higher in control subjects than in patients (t = 2.9, P = 0.004). There was no significant difference in serum levels of VEGF-C and VEGFR-2 between patients and controls. VEGF-C was associated with advanced tumor stage and presence of metastasis. VEGFR-1 was associated with metastasis, advanced overall stage, tumor differentiation and survival. VEGFR-2 levels were associated with poor tumor differentiation. There was no significant prognostic value for any of the VEGF family members or their receptors except for VEGFR-1 where high levels were associated with a poor overall survival. Conclusion: Serum VEGF levels vary significantly in the same cohort of patients with variable clinicopathological features and prognostic values. The simultaneous measurement of VEGF receptors levels in sera may overcome the limitations of a single biomarker assay.

Original languageEnglish
Pages (from-to)3879-3883
Number of pages5
JournalWorld Journal of Gastroenterology
Volume14
Issue number24
DOIs
Publication statusPublished - 2008

Fingerprint

Vascular Endothelial Growth Factor C
Vascular Endothelial Growth Factor Receptor-1
Vascular Endothelial Growth Factor Receptor-2
Vascular Endothelial Growth Factor A
Stomach
Adenocarcinoma
Serum
Vascular Endothelial Growth Factor D
Neoplasm Metastasis
Neoplasms
Vascular Endothelial Growth Factor Receptor
Survival
Stomach Neoplasms
Survival Rate
Biomarkers
Enzyme-Linked Immunosorbent Assay
Tissue Donors

Keywords

  • Gastric cancer
  • Oman
  • Serum
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma. / Al-Moundhri, Mansour S.; Al-Shukaili, A.; Al-Nabhani, M.; Al-Bahrani, B.; Burney, I. A.; Rizivi, A.; Ganguly, S. S.

In: World Journal of Gastroenterology, Vol. 14, No. 24, 2008, p. 3879-3883.

Research output: Contribution to journalArticle

@article{721aa11bb4ed4c908b965fc1fcbcaeb2,
title = "Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma",
abstract = "Aim: To analyze the serum levels and prognostic significance of vascular endothelial growth factor (VEGF) -A, -C, and -D, and their receptors, VEGFR-1 and -2 in gastric adenocarcinomas. Methods: The serum levels of VEGF family members were measured in 76 control subjects and 76 patients with gastric adenocarcinoma using an enzyme-linked immunosorbent assay (ELISA). These measurements were correlated with clinco-pathological features and survival rates. Results: The serum levels of VEGF-A and its receptor, VEGFR-1, were significantly higher in patients with gastric cancer than in healthy donors (t = 2.3, P = 0.02 and t = 4.2, P <0.0001, respectively). In contrast, the serum levels of VEGF-D were significantly higher in control subjects than in patients (t = 2.9, P = 0.004). There was no significant difference in serum levels of VEGF-C and VEGFR-2 between patients and controls. VEGF-C was associated with advanced tumor stage and presence of metastasis. VEGFR-1 was associated with metastasis, advanced overall stage, tumor differentiation and survival. VEGFR-2 levels were associated with poor tumor differentiation. There was no significant prognostic value for any of the VEGF family members or their receptors except for VEGFR-1 where high levels were associated with a poor overall survival. Conclusion: Serum VEGF levels vary significantly in the same cohort of patients with variable clinicopathological features and prognostic values. The simultaneous measurement of VEGF receptors levels in sera may overcome the limitations of a single biomarker assay.",
keywords = "Gastric cancer, Oman, Serum, Vascular endothelial growth factor",
author = "Al-Moundhri, {Mansour S.} and A. Al-Shukaili and M. Al-Nabhani and B. Al-Bahrani and Burney, {I. A.} and A. Rizivi and Ganguly, {S. S.}",
year = "2008",
doi = "10.3748/wjg.14.3879",
language = "English",
volume = "14",
pages = "3879--3883",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "24",

}

TY - JOUR

T1 - Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma

AU - Al-Moundhri, Mansour S.

AU - Al-Shukaili, A.

AU - Al-Nabhani, M.

AU - Al-Bahrani, B.

AU - Burney, I. A.

AU - Rizivi, A.

AU - Ganguly, S. S.

PY - 2008

Y1 - 2008

N2 - Aim: To analyze the serum levels and prognostic significance of vascular endothelial growth factor (VEGF) -A, -C, and -D, and their receptors, VEGFR-1 and -2 in gastric adenocarcinomas. Methods: The serum levels of VEGF family members were measured in 76 control subjects and 76 patients with gastric adenocarcinoma using an enzyme-linked immunosorbent assay (ELISA). These measurements were correlated with clinco-pathological features and survival rates. Results: The serum levels of VEGF-A and its receptor, VEGFR-1, were significantly higher in patients with gastric cancer than in healthy donors (t = 2.3, P = 0.02 and t = 4.2, P <0.0001, respectively). In contrast, the serum levels of VEGF-D were significantly higher in control subjects than in patients (t = 2.9, P = 0.004). There was no significant difference in serum levels of VEGF-C and VEGFR-2 between patients and controls. VEGF-C was associated with advanced tumor stage and presence of metastasis. VEGFR-1 was associated with metastasis, advanced overall stage, tumor differentiation and survival. VEGFR-2 levels were associated with poor tumor differentiation. There was no significant prognostic value for any of the VEGF family members or their receptors except for VEGFR-1 where high levels were associated with a poor overall survival. Conclusion: Serum VEGF levels vary significantly in the same cohort of patients with variable clinicopathological features and prognostic values. The simultaneous measurement of VEGF receptors levels in sera may overcome the limitations of a single biomarker assay.

AB - Aim: To analyze the serum levels and prognostic significance of vascular endothelial growth factor (VEGF) -A, -C, and -D, and their receptors, VEGFR-1 and -2 in gastric adenocarcinomas. Methods: The serum levels of VEGF family members were measured in 76 control subjects and 76 patients with gastric adenocarcinoma using an enzyme-linked immunosorbent assay (ELISA). These measurements were correlated with clinco-pathological features and survival rates. Results: The serum levels of VEGF-A and its receptor, VEGFR-1, were significantly higher in patients with gastric cancer than in healthy donors (t = 2.3, P = 0.02 and t = 4.2, P <0.0001, respectively). In contrast, the serum levels of VEGF-D were significantly higher in control subjects than in patients (t = 2.9, P = 0.004). There was no significant difference in serum levels of VEGF-C and VEGFR-2 between patients and controls. VEGF-C was associated with advanced tumor stage and presence of metastasis. VEGFR-1 was associated with metastasis, advanced overall stage, tumor differentiation and survival. VEGFR-2 levels were associated with poor tumor differentiation. There was no significant prognostic value for any of the VEGF family members or their receptors except for VEGFR-1 where high levels were associated with a poor overall survival. Conclusion: Serum VEGF levels vary significantly in the same cohort of patients with variable clinicopathological features and prognostic values. The simultaneous measurement of VEGF receptors levels in sera may overcome the limitations of a single biomarker assay.

KW - Gastric cancer

KW - Oman

KW - Serum

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=54349098298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54349098298&partnerID=8YFLogxK

U2 - 10.3748/wjg.14.3879

DO - 10.3748/wjg.14.3879

M3 - Article

VL - 14

SP - 3879

EP - 3883

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 24

ER -